Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Bipolar Disorder

ClinicalTrials.gov lists 1,656 trials for Bipolar Disorder or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 47.

MeSH D001714 Mental Disorders F03
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 66 Phase 1/2 Phase 1/2 21 Phase 2 Phase 2 133 Phase 2/3 Phase 2/3 22 Phase 3 Phase 3 207 Phase 4 Phase 4 232 Not applicable Not applicable 630 Observational Observational 345 Phase 1 Phase 1 66 Phase 1/2 Phase 1/2 21 Phase 2 Phase 2 133 Phase 2/3 Phase 2/3 22 Phase 3 Phase 3 207 Phase 4 Phase 4 232 Not applicable Not applicable 630 Observational Observational 345

Trials per phase (log scale)

1,656 of the 1,656 trials are tagged with Bipolar Disorder itself; the rest are tagged with a narrower condition beneath it.

Get the Bipolar Disorder report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Bipolar Disorder trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 86

1990: 1 trials (Observational 1) 1991: 1 trials (Observational 1) 1994: 2 trials (Observational 1, Phase 3 1) 1995: 3 trials (Phase 4 1, Phase 2 2) 1996: 4 trials (Observational 2, Phase 4 1, Phase 2 1) 1997: 4 trials (Phase 3 4) 1998: 3 trials (Observational 1, Not applicable 2) 1999: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 2000: 9 trials (Observational 2, Not applicable 2, Phase 3 3, Phase 2 2) 2001: 30 trials (Observational 4, Not applicable 2, Phase 4 8, Phase 3 7, Phase 2 4, Phase 1/2 2, Phase 1 3) 2002: 35 trials (Observational 4, Not applicable 9, Phase 4 9, Phase 3 10, Phase 2 3) 2003: 39 trials (Observational 1, Not applicable 10, Phase 4 13, Phase 3 11, Phase 2 4) 2004: 63 trials (Observational 7, Not applicable 4, Phase 4 18, Phase 3 26, Phase 2/3 1, Phase 2 6, Phase 1/2 1) 2005: 79 trials (Observational 12, Not applicable 12, Phase 4 24, Phase 3 22, Phase 2 6, Phase 1 3) 2006: 72 trials (Observational 9, Not applicable 12, Phase 4 16, Phase 3 18, Phase 2/3 1, Phase 2 7, Phase 1/2 3, Phase 1 6) 2007: 79 trials (Observational 18, Not applicable 17, Phase 4 22, Phase 3 9, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 4) 2008: 62 trials (Observational 12, Not applicable 14, Phase 4 15, Phase 3 11, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 1) 2009: 61 trials (Observational 13, Not applicable 14, Phase 4 9, Phase 3 12, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 6) 2010: 69 trials (Observational 14, Not applicable 20, Phase 4 17, Phase 3 9, Phase 2/3 3, Phase 1 6) 2011: 66 trials (Observational 18, Not applicable 26, Phase 4 9, Phase 3 6, Phase 2 3, Phase 1 4) 2012: 52 trials (Observational 12, Not applicable 16, Phase 4 6, Phase 3 6, Phase 2/3 4, Phase 2 5, Phase 1/2 2, Phase 1 1) 2013: 66 trials (Observational 17, Not applicable 32, Phase 4 2, Phase 3 5, Phase 2 6, Phase 1/2 1, Phase 1 3) 2014: 73 trials (Observational 11, Not applicable 44, Phase 4 7, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1 2) 2015: 62 trials (Observational 17, Not applicable 24, Phase 4 8, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1 2) 2016: 59 trials (Observational 18, Not applicable 24, Phase 4 4, Phase 3 7, Phase 2 3, Phase 1/2 1, Phase 1 2) 2017: 61 trials (Observational 11, Not applicable 30, Phase 4 7, Phase 3 2, Phase 2/3 1, Phase 2 7, Phase 1 3) 2018: 59 trials (Observational 11, Not applicable 31, Phase 4 2, Phase 3 4, Phase 2/3 2, Phase 2 6, Phase 1/2 1, Phase 1 2) 2019: 58 trials (Observational 10, Not applicable 30, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 4) 2020: 57 trials (Observational 19, Not applicable 29, Phase 4 4, Phase 3 2, Phase 2 2, Phase 1 1) 2021: 61 trials (Observational 11, Not applicable 35, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 3, Phase 1/2 3, Phase 1 3) 2022: 80 trials (Observational 15, Not applicable 48, Phase 4 4, Phase 3 1, Phase 2/3 1, Phase 2 9, Phase 1 2) 2023: 58 trials (Observational 11, Not applicable 31, Phase 4 6, Phase 3 1, Phase 2 6, Phase 1/2 1, Phase 1 2) 2024: 81 trials (Observational 22, Not applicable 41, Phase 4 2, Phase 3 5, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 3) 2025: 86 trials (Observational 27, Not applicable 42, Phase 4 3, Phase 3 6, Phase 2 5, Phase 1/2 1, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 48
2025 86
2024 81
2023 58
2022 80
2021 61
2020 57
2019 58
2018 59
2017 61

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 65 trials starting in 2026 and about 73 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 136 trials still running at the 2026-10-09 snapshot; registered median of 32 months across 1,060 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Bipolar Disorder trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 66
Phase 1/2 21
Phase 2 133
Phase 2/3 22
Phase 3 207
Phase 4 232
Not applicable 630
Observational 345

How many Bipolar Disorder trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 39
Recruiting 166
Enrolling by invitation 12
Active, not recruiting 35
Completed 1,044

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Bipolar Disorder trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 47
National Institute of Mental Health (NIMH) 41
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 21
VA Office of Research and Development 21
Eli Lilly and Company 19

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Bipolar Disorder? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
LI 49
Aripiprazole 43
PMI-150 (intranasal ketamine) 34
Sodium Valproate 15

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
IR (Immediate-Release) quetiapine fumarate (drug) 65
IM olanzapine 43
Lamotrigine use 42
IR Risperidone 34
only ziprasidone 33

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Bipolar Disorder trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
In Patient Hospitalization 1,436 1
Psychiatric hospitalization 268 2
Suicide Attempt 243 11
Mania 201 37
Medical hospitalization 169 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Bipolar Disorder? (1,943)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Clinical outcomes of youth at familial risk for bipolar disorder: A 2-year longitudinal, observational study. Journal of affective disorders 2026 Yes
Antidepressant efficacy and safety of scopolamine in individuals with bipolar disorder (SCOPE-BD): A randomized double-blind placebo-controlled trial. Journal of affective disorders 2026 Yes
The Ottawa sunglasses at night study: A randomized controlled trial of blue-blocking glasses for mania. Journal of affective disorders 2026 Yes
Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials. Advances in therapy 2025 Yes
Efficacy of Lumateperone in depression associated with bipolar II disorder: a pooled analysis of late-phase clinical trials. CNS spectrums 2025 Yes

Showing 5 of 1,943 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages